<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208151">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378352</url>
  </required_header>
  <id_info>
    <org_study_id>999905255</org_study_id>
    <secondary_id>05-AG-N255</secondary_id>
    <nct_id>NCT00378352</nct_id>
  </id_info>
  <brief_title>REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction</brief_title>
  <official_title>Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Large Myocardial Infarctions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether erythropoietin can help limit the damage to
      the heart in patients with acute heart attacks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      REVEAL is a randomized, double-blinded, placebo-controlled, parallel phase II clinical study
      that will evaluate the effects of erythropoietin administration on infarct size, left
      ventricular remodeling and circulating endothelial progenitor cells in patients with large
      myocardial infarctions (MI). The study will be conducted in two phases: a dose-escalation
      safety phase and a single dose efficacy phase. Eligible patients who present to the hospital
      with an acute ST-elevation MI and who agree to participate in this study will be randomly
      assigned to receive a single infusion of study medication consisting either of
      erythropoietin or placebo. The size of the infarction and the dimensions of the heart will
      be assessed by cardiac magnetic resonance imaging (MRI) within 2-6 days of the infusion of
      the study medication, and again approximately 3 months later.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in infarct size, as assessed by magnetic resonance imaging</measure>
    <time_frame>within 2-6 days of administration of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>End-systolic volume, ejection fraction</measure>
    <time_frame>Within 2-6 days of administration of study medication, and 3 months later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of circulating endothelial progenitor cells</measure>
    <time_frame>Within 2-6 days of administration of study medication, and 3 months later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in infarct size</measure>
    <time_frame>3 months after administration of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin levels</measure>
    <time_frame>During the first two weeks following study medication administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of death or arterial or venous thrombotic events</measure>
    <time_frame>Within 4 weeks following administration of study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Acute ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>15,000 Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single parenteral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30,000 Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single parenteral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60,000 Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single parenteral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single parenteral administration of saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoietin Alfa</intervention_name>
    <arm_group_label>15,000 Units</arm_group_label>
    <arm_group_label>30,000 Units</arm_group_label>
    <arm_group_label>60,000 Units</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Age greater than 21 years

        Acute ST-elevation myocardial infarction

        Referral for primary or rescue angioplasty

        Revascularization procedure within 8 hours from the onset of ischemic symptoms

        TIMI (Thrombolysis in myocardial infarction) flow grade 0 or 1 in the culprit coronary
        artery at the beginning of coronary angiography

        Successful revascularization of infarct-related artery

        EXCLUSION CRITERIA:

        Clinical indication for erythropoietin

        STEMI (ST-elevation myocardial infarction) due to occlusion of a branch vessel

        Any history of prior MI, PCI (Percutaneous coronary intervention), CABG (Coronary artery
        bypass graft), cardiomyopathy, myocarditis, or CHF (congestive heart failure)

        Hypersensitivity to human albumin, mammalian cell-derived products, or erythropoietin

        Hematocrit greater than 42% in men or greater than 40% in women at the time of study drug
        administration

        Uncontrolled hypertension at the time of study drug administration

        Cardiogenic shock

        Need for coronary surgical revascularization as determined at the time of the index
        coronary catheterization

        History of hypercoagulable disorder, thromboembolic event, or venous thrombosis

        History of stroke or TIA (transient ischemic attack)

        History of seizures

        Contraindication to MRI

        Pregnancy or nursing mother
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward G Lakatta, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Aging (NIA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073-6769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-4872</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Heart and Vascular Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Cardiovascular Magnetic Resonance Institute</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <zip>37027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res. 2004 Aug 1;63(2):208-16. Review.</citation>
    <PMID>15249178</PMID>
  </reference>
  <reference>
    <citation>Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003 Oct;112(7):999-1007.</citation>
    <PMID>14523037</PMID>
  </reference>
  <reference>
    <citation>Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005 Jan 5;293(1):90-5. Review.</citation>
    <PMID>15632341</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>June 28, 2012</lastchanged_date>
  <firstreceived_date>September 18, 2006</firstreceived_date>
  <responsible_party>
    <name_title>Edward G. Lakatta, M.D./National Institute on Aging</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Left Ventricular Remodeling</keyword>
  <keyword>Cardiac Magnetic Resonance Imaging</keyword>
  <keyword>Endothelial Progenitor Cells</keyword>
  <keyword>Infarct Size</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
